Legal Representation
Attorney
Ann Lamport Hammitte
Application History
50 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Mar 18, 2025 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Mar 18, 2025 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Mar 18, 2025 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Mar 18, 2025 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Mar 18, 2025 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Mar 18, 2025 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Feb 25, 2025 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Feb 25, 2025 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Feb 25, 2025 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Feb 25, 2025 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Feb 25, 2025 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Feb 25, 2025 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Jan 18, 2025 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Jan 18, 2025 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Jan 18, 2025 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Jan 17, 2025 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Jan 17, 2025 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Jan 17, 2025 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Nov 1, 2024 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Nov 1, 2024 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Nov 1, 2024 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Nov 1, 2024 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Nov 1, 2024 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Nov 1, 2024 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Oct 31, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Oct 31, 2024 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Oct 31, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Oct 31, 2024 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Oct 31, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Oct 31, 2024 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Oct 31, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Oct 31, 2024 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Oct 31, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Oct 31, 2024 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Oct 31, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Oct 31, 2024 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| May 3, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 3, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 3, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 2, 2024 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| May 2, 2024 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| May 2, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 2, 2024 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| May 2, 2024 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| May 2, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 2, 2024 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| May 2, 2024 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| May 2, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Oct 26, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Oct 26, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
Detailed Classifications
Class 005
Medicated gels for therapeutic use in the nature of therapeutic pharmaceuticals containing ammonia oxidizing bacteria for the treatment of inflammatory diseases, for the treatment of systemic diseases, namely, hypertension, other cardiovascular and circulatory disorders, and primary and secondary headache disorders including migraine, and to counteract skin damage caused by UV exposure or aging; medicated creams for therapeutic use in the nature of therapeutic pharmaceuticals containing ammonia oxidizing bacteria for the treatment of inflammatory diseases, for the treatment of systemic diseases, namely, hypertension, other cardiovascular and circulatory disorders, and primary and secondary headache disorders including migraine, and to counteract skin damage caused by UV exposure or aging; medicated sprays for therapeutic use in the nature of therapeutic pharmaceuticals containing ammonia oxidizing bacteria for the treatment of inflammatory diseases, for the treatment of systemic diseases, namely, hypertension, other cardiovascular and circulatory disorders, and primary and secondary headache disorders including migraine, and to counteract skin damage caused by UV exposure or aging; nasal sprays for therapeutic use; topical applications in the nature of gels, creams, sprays, and liquids for therapeutic use, namely, topical preparations containing ammonia oxidizing bacteria for the treatment of skin disorders, acne, inflammation, eye disorders, migraines, headaches, allergic reactions, insomnia, hypertension, thermoregulation, and to promote wound healing; medicated liquids for therapeutic use in the nature of therapeutic pharmaceuticals for the treatment of inflammatory diseases, for the treatment of systemic diseases, namely, hypertension, other cardiovascular and circulatory disorders, and primary and secondary headache disorders including migraine, and to counteract skin damage caused by UV exposure or aging; biological therapeutics being pharmaceutical preparations for treatment of skin disorders, circulatory and cardiovascular disorders, neurologic diseases, inflammation, gastrointestinal disorders, respiratory disorders, eye disorders, urogenital disorders, auditory disorders, migraines, headaches, allergic rhinitis, insomnia, hyperhidrosis, acne, and hypertension; therapeutic agents for thermoregulation and promoting wound healing
First Use Anywhere:
Sep 12, 2024
First Use in Commerce:
Sep 12, 2024
Classification
International Classes
005